140 How many locally advanced NSCLC patients receive Durvalumab and what are the limiting factors?

Durvalumab is recommended for treatment of inoperable stage 3 non-small cell lung cancers (NSCLC), in PDL1 positive patients who have not progressed on platinum-based chemo-radiation (cCRT). Additional factors can prevent or limit the use of Durvalumab. The aim of this retrospective audit was to explore how many stage 3 NSCLC patients treated in our department received Durvalumab, how many cycles they received, and to explore why Durvalumab was either not offered or discontinued.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Radiotherapy Source Type: research